Physician profile
Karin A True
NPI 1730110065
$2,327.39
in general payments reported to CMS, 2019-2025
8 companies · $302 in 2025
The $302 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $75.38 · 2022: $80.63 · 2023: $314 · 2024: $1,555 · 2025: $302.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,099 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $750 · Food and Beverage: $302 · Education: $19.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,099.24 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $750.00 |
| Food and Beverage | $302.33 |
| Education | $19.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $1,869.05 | 2023-2024 | Prevymis |
| One Lambda, INC. | $146.11 | 2025 | |
| Sanofi-Aventis U.S. LLC | $130.99 | 2025 | |
| Glaxosmithkline, LLC. | $80.63 | 2022 | |
| Opko Pharmaceuticals, LLC | $75.38 | 2019 | |
| Fresenius USA Marketing, INC. | $25.23 | 2025 | Crit-Line |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karin True listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.